SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Epigral informs about analyst meet

15 Jan 2026 Evaluate

Pursuant to Regulation 30 and Para (A) of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Epigral has informed that the Company is having meeting with Analyst / Investor ‘UTI Asset Management Company’ on 16th January, 2026 (One-on-One) through Video Conferencing (V.C.). The latest Earnings Presentation and Corporate Presentation to be discussed have already been placed on the website of the Company; www.epigral.com. No unpublished price sensitive information will be shared/discussed in the meeting with the Investors.

The above information is a part of company’s filings submitted to BSE.

Epigral Share Price

1179.90 13.30 (1.14%)
21-Apr-2026 13:07 View Price Chart
Peers
Company Name CMP
BASF India 3685.40
Tata Chemicals 709.00
SRF 2479.95
Pidilite Inds. 1398.20
Deepak Nitrite 1621.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×